A Study of CM310 in Subjects With Moderate to Severe Asthma

Summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 24-week randomized treatment period, and a 8-week safety follow-up period.

Timeline

Start

2022-01-12

Primary completion

2023-09-13

Completion

2023-09-13

Drugs

Indications